GlaxoSmithKline: withdraws from Pfizer unit sale process
(CercleFinance.com) - The day after Reckitt Benckiser threw in the towel, GlaxoSmithKline confirmed on Friday that it is also withdrawing from the process of buying Pfizer's consumer healthcare unit.
"While we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation," CEO Emma Walmsley simply commented.
London-listed GSK shares were up 2.9% at 1,310.8 pence after this statement.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
"While we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation," CEO Emma Walmsley simply commented.
London-listed GSK shares were up 2.9% at 1,310.8 pence after this statement.
Copyright (c) 2018 CercleFinance.com. All rights reserved.